Status of group B streptococcal CROSSMARK_logo_3_Test 1 / 1 vaccine development

다국어 초록 (Multilingual Abstract)

Streptococcus agalactiae (group B streptococcus, GBS) is a leading causal organism of neonatal invasive diseases and severe infections in the elderly. Despite significant advances in the diagnosis and treatment of GBS infections and improvement in personal hygiene standards, this pathogen is still a global health concern. Thus, an effective vaccine against GBS would augment existing strategies to substantially decrease GBS infection. In 2014, World Health Organization convened the first meeting for consultation on GBS vaccine development, focusing on the GBS maternal immunization program, which was aimed at reducing infections in neonates and young infants worldwide. Here, we review the history of GBS infections, the current vaccine candidates, and the current status of immunogenicity assays used to evaluate the clinical efficacy of GBS vaccines.

참고문헌 (Reference)

1 Lin SM, "Vaccination with a latch peptide provides serotype-independent protection against group B streptococcus infection in mice" 217 : 93-102, 2017

2 Manning SD, "The frequency of genes encoding three putative group B streptococcal virulence factors among invasive and colonizing isolates" 6 : 116-, 2006

3 Doro F, "Surfome analysis as a fast track to vaccine discovery: identification of a novel protective antigen for group B streptococcus hypervirulent strain COH1" 8 : 1728-1737, 2009

4 Baker CJ, "Suppurative meningitis due to streptococci of Lancefield group B: a study of 33 infants" 82 : 724-729, 1973

5 Nuccitelli A, "Structure-based approach to rationally design a chimeric protein for an effective vaccine against group B streptococcus infections" 108 : 10278-10283, 2011

6 Heath PT, "Status of vaccine research and development of vaccines for GBS" 34 : 2876-2879, 2016

7 Macauley MS, "Siglec-mediated regulation of immune cell function in disease" 14 : 653-666, 2014

8 Chaffin DO, "Sialylation of group B streptococcal capsular polysaccharide is mediated by cpsK and is required for optimal capsule polymerization and expression" 187 : 4615-4626, 2005

9 Teatero S, "Serotype distribution, population structure, and antimicrobial resistance of group B streptococcus strains recovered from colonized pregnant women" 55 : 412-422, 2017

10 Slotved HC, "Serotype IX, a proposed new Streptococcus agalactiae serotype" 45 : 2929-2936, 2007

11 Flores AR, "Sequence type 1 group B streptococcus, an emerging cause of invasive disease in adults, evolves by small genetic changes" 112 : 6431-6436, 2015

12 Aoyagi Y, "Role of L-ficolin/mannose-binding lectin-associated serine protease complexes in the opsonophagocytosis of type III group B streptococci" 174 : 418-425, 2005

13 Zhao Z, "Reverse line blot assay for direct identification of seven Streptococcus agalactiae major surface protein antigen genes" 13 : 145-149, 2006

14 Giersing BK, "Report from the World Health Organization's Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 7-9th Sep 2015" 34 : 2865-2869, 2016

15 Guttormsen HK, "Quantitative determination of antibodies to type III group B streptococcal polysaccharide" 173 : 142-150, 1996

16 Larsson C, "Protection against experimental infection with group B streptococcus by immunization with a bivalent protein vaccine" 17 : 454-458, 1999

17 Verani JR, "Prevention of perinatal group B streptococcal disease: revised guidelines from CDC, 2010" 59 : 1-36, 2010

18 Fry RM, "Prevention and control of puerperal sepsis: bacteriological aspects" 2 : 340-342, 1938

19 Muller-Graf CD, "Population biology of Streptococcus pneumoniae isolated from oropharyngeal carriage and invasive disease" 145 : 3283-3293, 1999

20 Kalliola S, "Neonatal group B streptococcal disease in Finland: a ten-year nationwide study" 18 : 806-810, 1999

21 Baker JA, "Mucosal vaccination promotes clearance of Streptococcus agalactiae vaginal colonization" 35 : 1273-1280, 2017

22 Lachenauer CS, "Mosaicism in the alpha-like protein genes of group B streptococci" 97 : 9630-9635, 2000

23 Kong F, "Molecular profiles of group B streptococcal surface protein antigen genes: relationship to molecular serotypes" 40 : 620-626, 2002

24 Doran KS, "Molecular pathogenesis of neonatal group B streptococcal infection: no longer in its infancy" 54 : 23-31, 2004

25 Meehan M, "Molecular epidemiology of group B streptococci in Ireland reveals a diverse population with evidence of capsular switching" 33 : 1155-1162, 2014

26 Ramaswamy SV, "Molecular characterization of nontypeable group B streptococcus" 44 : 2398-2403, 2006

27 "Minervax" Minervax

28 Seale AC, "Maternal colonization with Streptococcus agalactiae and associated stillbirth and neonatal disease in coastal Kenya" 1 : 16067-, 2016

29 Baker CJ, "Maternal antibody at delivery protects neonates from early onset group B streptococcal disease" 209 : 781-788, 2014

30 Rioux S, "Localization of surface immunogenic protein on group B streptococcus" 69 : 5162-5165, 2001

31 Lin FY, "Level of maternal IgG anti-group B streptococcus type III antibody correlated with protection of neonates against early-onset disease caused by this pathogen" 190 : 928-934, 2004

32 Madrid L, "Infant group B streptococcal disease incidence and serotypes worldwide: systematic review and meta-analyses" 65 (65): S160-S172, 2017

33 Skoff TH, "Increasing burden of invasive group B streptococcal disease in nonpregnant adults, 1990-2007" 49 : 85-92, 2009

34 Fluegge K, "Incidence and clinical presentation of invasive neonatal group B streptococcal infections in Germany" 117 : e1139-e1145, 2006

35 Edwards MS, "Immune responses to invasive group B streptococcal disease in adults" 22 : 1877-1883, 2016

36 Johri AK, "Group B streptococcus: global incidence and vaccine development" 4 : 932-942, 2006

37 Nuccitelli A, "Group B streptococcus vaccine: state of the art" 3 : 76-90, 2015

38 Gourlay LJ, "Group B streptococcus pullulanase crystal structures in the context of a novel strategy for vaccine development" 191 : 3544-3552, 2009

39 Schuchat A, "Group B streptococcus" 353 : 51-56, 1999

40 Areschoug T, "Group B streptococcal surface proteins as targets for protective antibodies: identification of two novel proteins in strains of serotype V" 67 : 6350-6357, 1999

41 Franciosi RA, "Group B streptococcal neonatal and infant infections" 82 : 707-718, 1973

42 Neto MT, "Group B streptococcal disease in Portuguese infants younger than 90 days" 93 : F90-F93, 2008

43 Barton LL, "Group B beta hemolytic streptococcal meningitis in infants" 82 : 719-723, 1973

44 Paoletti LC, "Glycoconjugate vaccines to prevent group B streptococcal infections" 3 : 975-984, 2003

45 Larsson C, "Experimental vaccination against group B streptococcus, an encapsulated bacterium, with highly purified preparations of cell surface proteins Rib and alpha" 64 : 3518-3523, 1996

46 Klegerman ME, "Estimation of the protective level of human IgG antibody to the type-specific polysaccharide of group B streptococcus type Ia" 148 : 648-655, 1983

47 Alhhazmi A, "Epidemiology of invasive group B streptococcal disease in Alberta, Canada, from 2003 to 2013" 54 : 1774-1781, 2016

48 Schuchat A, "Epidemiology of group B streptococcal disease in the United States: shifting paradigms" 11 : 497-513, 1998

49 Toyofuku M, "Effects of intrapartum antibiotic prophylaxis on neonatal acquisition of group B streptococci" 190 : 169-173, 2017

50 Hansen SM, "Dynamics of Streptococcus agalactiae colonization in women during and after pregnancy and in their infants" 42 : 83-89, 2004

51 Choi MJ, "Development of a multiplexed opsonophagocytic killing assay (MOPA) for group B streptococcus" 14 : 67-73, 2018

52 Burton RL, "Development of a fourfold multiplexed opsonophagocytosis assay for pneumococcal antibodies against additional serotypes and discovery of serological subtypes in Streptococcus pneumoniae serotype 20" 19 : 835-841, 2012

53 Burton RL, "Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies" 13 : 1004-1009, 2006

54 Baker CJ, "Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection" 294 : 753-756, 1976

55 Bellais S, "Capsular switching in group B streptococcus CC17 hypervirulent clone: a future challenge for polysaccharide vaccine development" 206 : 1745-1752, 2012

56 Madhi SA, "Antibody kinetics and response to routine vaccinations in infants born to women who received an investigational trivalent group B streptococcus polysaccharide CRM197-conjugate vaccine during pregnancy" 65 : 1897-1904, 2017

57 Leroux-Roels G, "A randomized, observer-blind Phase Ib study to identify formulations and vaccine schedules of a trivalent group B streptococcus vaccine for use in non-pregnant and pregnant women" 34 : 1786-1791, 2016

58 Chen VL, "A maternal vaccine against group B streptococcus: past, present, and future" 31 (31): D13-D19, 2013